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The Editorial on the Research Topic
Advances in the Prevention and Treatment of Inflammation-Associated Preterm Birth
Despite the widely appreciated fact that preterm birth (PTB) is a syndrome and the potential conse-
quence of many different pathways (1), there is now unequivocal evidence that inflammation lies at 
the core of the majority of the pathophysiological causes of PTB. Inflammation within the amniotic 
cavity – characterized by chorioamnionitis and/or elevated levels of amniotic fluid cytokines and 
chemokines – is the major driver of preterm labor less than 34 weeks gestation and an important 
contributor to later preterm deliveries (2–4). However, the causes of the inflammation and the strate-
gies by which it can be safely and effectively prevented and treated are less clear and the subject of 
ongoing investigation and debate. While ascending bacterial infection is a particularly important 
and well-studied cause of inflammation-associated PTB in very preterm deliveries, other “sterile” 
causes are dominant at later gestational ages. The nature, localization, timing, and extent of the 
inflammatory insult likely determine the obstetric outcome and degree of risk to the fetus. These 
factors also dictate possible pharmacotherapeutic approaches that might be employed to achieve 
better pregnancy outcomes – namely, minimal neonatal morbidity and optimal long-term health 
and development of the child.
In this research topic, we have invited contributions from a range of internationally recognized 
clinicians and scientists relating to inflammation-associated PTB from both the causal and thera-
peutic perspectives. To place the discussions in the broader clinical context, Newnham et al. describe 
the problem of PTB and major intervention strategies that are being applied in clinics around the 
world to prevent PTB. They outline the evidence supporting efficacy and safety, and the likely impact 
of clinical implementation on PTB rates. They contend that we are now in a position to translate 
research into clinical care, although such interventions will require integration and coordination of 
multidisciplinary teams, tailored to different communities and resource settings. Next, Kemp dis-
cusses the immunological factors involved in pathogenesis of fetal inflammatory response syndrome 
(FIRS), with special emphasis on the role of pattern recognition receptors, defensins, and comple-
ment activation. He reviews, in detail, the evidence for a fetal contribution to the overall intrauterine 
inflammatory response to microbial infection and its significance with respect to neonatal sequelae.
Following on, Payne and Bayatibojakhi outline the roles played by different microorganisms 
(bacteria, fungi, yeasts, and viruses) in the process of infection-driven PTB and the contribution 
of microbiome studies to our understanding of this topic. They reiterate the important point that 
intra-amniotic infection is frequently a polymicrobial disease and discuss technical aspects related 
to the generation and interpretation of microbiome data – in particular the “disconnect” between 
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DNA-based identification and presence of viable microorgan-
isms. The recent study by Prince et al. (5) further contributes to 
this topic, providing novel links between the microbiome and the 
metabolome in preterm deliveries. Continuing with the micro-
bial-inflammation theme, Ireland and Keelan move the focus to 
the maternal response to infection and the serological response to 
Ureaplasma, in particular. While this intracellular microorganism 
is known to be commonly associated with inflammation-driven 
PTB, the relatively low incidence of infection-associated PTB 
in the presence of high vaginal Ureaplasma-colonization rates 
(~50% in pregnancy) remains unexplained. This review explores 
the role of the maternal host response to colonization in deter-
mining risk and pregnancy outcomes. Next, Menon overviews 
the role of oxidative stress as a driver of PTB and preterm prelabor 
rupture of membranes (PPROM). He examines the evidence sup-
porting the contribution of reactive oxygen species (ROS) to the 
pathogenesis of PPROM and PTB and the pregnancy conditions 
that may give rise to ROS generation and downstream adverse 
effects: MAPK activation, telomere reduction, DNA damage, 
senescence, and apoptosis. He suggests that the release of secreted 
senescence biomarkers may play a key role in the triggering of 
PTB and PPROM and, as such, are targets for new interventional 
strategies. A recent publication from his group reinforces the 
theme of this review (6).
From inflammatory pathophysiology we move to therapy. 
Ng et  al. commence by exploring the potential of novel anti-
inflammatory drugs to block inflammatory signaling and prevent 
the release of cytokines and other mediators that trigger labor and 
delivery and cause inflammation-associated fetal morbidity. They 
discuss the efficacy of a range of compounds and then discuss 
the barriers to clinical translation and the challenges of adopt-
ing such anti-inflammatory strategies in different pregnancy 
scenarios. Next, Yang et  al. examine the potential application 
of administration of probiotics to prevent PTB. They initially 
discuss the evidence supporting an association between altered 
vaginal microbiome and adverse pregnancy outcome, looking at 
the relationship between the presence of different Lactobacillus 
species and PTB rates, in different populations. They, then, 
review the evidence from their own studies (and others) on the 
properties and applications of probiotics, such as Lactobacillus 
rhamnosus GR-1, for preventing PTB. They conclude that the 
strategy holds promise, but large scale clinical trials are required 
with appropriate power to demonstrate the benefits and risks. A 
recent trial of oral probiotics (L. rhamnosus GR-1 plus L. reuteri 
RC-14) supports the potential effectiveness of the approach in 
terms of normalizing vaginal microbiota (7).
Lamont, then, reviews the evidence around the use of 
antibiotics for the prevention of PTB, looking at the results 
of clinical trials and meta-analyses and pointing to errors 
in their design and conclusions. He stresses the importance 
of applying the right therapy at the right time to the right 
cohort of patients and points to the success of studies using 
clarithromycin early in pregnancy to treat women with 
abnormal vaginal microbiota. Finally, Keelan et  al. discuss 
the potential applications of a new macrolide antibiotic, 
solithromycin, in the prevention and treatment of pregnancy 
infections and PTB. Drawing on their own studies in human 
placentas and the pregnant sheep model, combined with other 
data on antimicrobial efficacy, they discuss the potency of 
solithromycin against the organisms that typically infect the 
amniotic cavity. This review also highlights solithromycin’s 
unique ability to cross the placenta and treat the infection at 
its source following oral maternal administration.
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